2025-09-03+00:0006:34:26+00:00447370RES-0001selec-wTEN-0001tenders1CON-0001LOT-0000TEN-0001447370noTPA-0001LOT-0000Alamar QuoteCON-00012025-08-06Z2025-09-01ZORG-0001043-1633/25-7000TEN-0001TPA-0001ORG-000429http://www.ku.dk/ORG-0001Københavns UniversitetNørregade 10København K1165DK011DNK29979812Bettina Petersen+45 35327223bettina.dion@adm.ku.dkhttps://naevneneshus.dk/start-din-klage/klagenaevnet-for-udbud/ORG-0002Klagenævnet for UdbudNævnenes Hus, Toldboden 2Viborg8800DK041DNK37795526+45 72405600klfu@naevneneshus.dkhttps://www.kfst.dkORG-0003Konkurrence- og ForbrugerstyrelsenCarl Jacobsens vej 35Valby2500DK011DNK10294819+45 41715000kfst@kfst.dkmediumORG-0004Alamar Biosciences Europe SrlVia Amedeo Modigliani, 45 Segrate – Milan20054ITC4CITA13467230960Sandra Kyrk+46767607277 skyrk@alamarbio.comhttp://mercell.com/ORG-0005Mercell Holding ASAAskekroken 11Oslo0277NO081NOR980921565eSender+47 21018800+47 21018801publication@mercell.com00576112-2025169/20252025-09-04+02:002.3eforms-sdk-1.13506b76a2-792e-4e51-b1d1-a8db299bd6340aaf96c4-fc38-4448-bfff-56e8132c61ad2025-09-03+00:0006:33:48+00:000132014L0024can-standardDANhttps://eu.eu-supply.com/ctm/company/companyinformation/index/166597body-pleducationORG-0001ted-esenORG-0005neg-wo-call58583f56-49e6-43c6-975d-8759a7a669a9-01exclusiveKey technical and scientific differentiators that exclude alternative suppliers: • Patent-protected technology: The NULISA™ platform is protected by multiple patents (including US20210278398A1, U.S. Patent No. 12105084, U.S. Patent No. 12188929, and EU Patent EP4069731A1), granting ALAMAR Biosciences exclusive rights to manufacture and distribute the system and its associated technologies. • Fully automated high-throughput platform: The ARGO™ HT integrates all sample preparation and analysis steps within a single instrument, including an embedded qPCR system and support for Next Generation Sequencing (NGS). It enables multiplexed analysis of up to 1,000 protein targets across 96 to 288 samples per run. • High sensitivity and specificity: The system leverages oligonucleotide-conjugated antibodies and a proprietary dual capture-and-release mechanism, which dramatically reduces background noise and delivers highly accurate and reproducible results. • Time efficiency and ease of use: The platform requires less than 30 minutes of hands-on time, with singleplex results available in under 6 hours, and multiplex results in under 15 hours, making it one of the most efficient solutions currently available.043-1633/25-7000Automated Proteomics SystemThe purpose of the acquisition of the ARGO™ HT System is to expand the service portfolio of the Proteomics Research Infrastructure (PRI) by implementing NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology, which enables highly sensitive proteomic analyses and the precise quantification of low-abundance biomarkers complementary to existing proteomic pipelines at PRI. The ARGO™ HT System is a technologically unique platform based on the patented NULISA™ technology, which enables ultra-sensitive protein detection at attomolar concentrations—a level of sensitivity unattainable with conventional proteomics platforms.supplies38433100DK011DNKLOT-0000no-eu-fundsfix-unit1qualitykun en leverandør muligKey technical and scientific differentiators that exclude alternative suppliers: • Patent-protected technology: The NULISA™ platform is protected by multiple patents (including US20210278398A1, U.S. Patent No. 12105084, U.S. Patent No. 12188929, and EU Patent EP4069731A1), granting ALAMAR Biosciences exclusive rights to manufacture and distribute the system and its associated technologies. • Fully automated high-throughput platform: The ARGO™ HT integrates all sample preparation and analysis steps within a single instrument, including an embedded qPCR system and support for Next Generation Sequencing (NGS). It enables multiplexed analysis of up to 1,000 protein targets across 96 to 288 samples per run. • High sensitivity and specificity: The system leverages oligonucleotide-conjugated antibodies and a proprietary dual capture-and-release mechanism, which dramatically reduces background noise and delivers highly accurate and reproducible results. • Time efficiency and ease of use: The platform requires less than 30 minutes of hands-on time, with singleplex results available in under 6 hours, and multiplex results in under 15 hours, making it one of the most efficient solutions currently available.I henhold til lov om Klagenævnet for Udbud26 gælder følgende frist for indgivelse af klage: » Klage over ikke at være blevet prækvalificeret skal være indgivet til Klagenævnet for Udbud inden 20 kalenderdage fra dagen efter afsendelse af en underretning til de berørte ansøgere om, hvem der er blevet udvalgt, jf. udbudslovens § 171, stk. 2, eller klagenævnslovens § 2, stk. 1, nr. 1, når underretningen er ledsaget af en begrundelse for beslutningen. I andre situationer skal klage over udbud være indgivet til Klagenævnet for Udbud in den: 1. 45 kalenderdage efter, at ordregiveren har offentliggjort en bekendtgørelse i Den Europæiske Unions Tidende om, at ordregiveren har indgået en kontrakt. Fristen regnes fra dagen efter den dag, hvor bekendtgørelsen er blevet offentliggjort. 2. 30 kalenderdage regnet fra dagen efter den dag, hvor ordregiveren har underrettet de berørte tilbudsgivere om, at en kontrakt baseret på en rammeaftale med genåbning af konkurrencen eller et dynamisk indkøbssystem er indgået, hvis underretningen har angivet en begrundelse for beslutningen. 3. seks måneder efter, at ordregiveren har indgået en rammeaftale, regnet fra dagen efter den dag, hvor ordregiveren har underrettet de berørte ansøgere og tilbudsgivere, jf. klagenævns lovens § 2, stk. 2, eller udbudslovens § 171, stk. 4. 4. 20 kalenderdage regnet fra dagen efter, at ordregiveren har meddelt sin beslutning, jf. ud budslovens § 185, stk. 2. Senest samtidig med at en klage indgives til Klagenævnet for Udbud, skal klageren skriftligt underrette ordregiveren om, at en klage indgives til Klagenævnet for Udbud, og om, hvorvidt klagen er indgivet i standstill-perioden, jf. klagenævnslovens § 6, stk. 4. I tilfælde, hvor klagen ikke er indgivet i standstill-perioden, skal klageren tillige angive, hvorvidt der begæres opsættende virkning af klagen, jf. klagenævnslovens § 12, stk. 1.ORG-0003ORG-0002truefalsenonenone043-1633/25-7000Automated Proteomics SystemThe purpose of the acquisition of the ARGO™ HT System is to expand the service portfolio of the Proteomics Research Infrastructure (PRI) by implementing NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology, which enables highly sensitive proteomic analyses and the precise quantification of low-abundance biomarkers complementary to existing proteomic pipelines at PRI. The ARGO™ HT System is a technologically unique platform based on the patented NULISA™ technology, which enables ultra-sensitive protein detection at attomolar concentrations—a level of sensitivity unattainable with conventional proteomics platforms.supplies38433100DK011DNK2000-01-01Z